Who can administer
  
                  May be administered by registered competent doctor or nurse/midwife
      
  
        Important information
  
                  
- Crystallisation may occur - see under 'storage requirements' for further information
 
- See 'Monitoring requirements' below
 
- Flush line with Glucose 5% as there is a risk of precipitation with Sodium chloride 0.9% (ref 1)
 
- Administer via central line or large peripheral vein
 
- Extravasation causes inflammation and thrombophlebitis
 
      
  
        Available preparations
  
                  Mannitol 10% 500mL infusion (50g in 500mL)
Mannitol 15% 500mL infusion (75g in 500mL)
Mannitol 20% 500mL infusion (100g in 500mL) (this product may not be available- it has been discontinued by some manufacturers)
      
  
        Reconstitution
  
                  Already in solution
      
  
        Infusion fluids
  
                  Not required - product ready for infusion
      
  
        Methods of intravenous administration
  
                  Slow intravenous injection (test dose for patients with marked oliguria or suspected inadequate renal function)
- Test dose over 3 to 5 minutes
 
Intermittent intravenous infusion
- See under 'dose' for details
 
- Administer via a giving set that incorporates a 15 micron in-line filter (ref 1) - check packaging of administration set for details)- see photo
 
- 
	

 
- The rate of infusion is usually adjusted to maintain a urine flow of at least 30 to 50mL/hour
 
- In emergency situations, the maximum infusion rate can be as high as 0.2g/kg over five minutes
 
      
  
        Dose in adults
  
                  
| Volume in ml of Mannitol solution required | 
 | 
Required dose | 
15g | 
25g | 
50g | 
75g | 
100g | 
150g | 
| 10% solution | 
 | 
150ml | 
250ml | 
500ml | 
750ml | 
1000ml | 
1500ml | 
| 15% solution | 
 | 
100ml | 
167ml | 
333ml | 
500ml | 
667ml | 
1000ml | 
| 20% solution | 
 | 
75ml | 
125ml | 
250ml | 
375ml | 
500ml | 
750ml | 
Reduction of intracranial pressure, cerebral volume and intraocular pressure 
- Usual dose: 1.5 to 2g/kg infused over 30 to 60 minutes (some references suggest a range of 0.25 to 2g/kg (ref 2))
 
- Dose may be repeated once or twice after 4 to 8 hours (ref 2)
 
- See table above for guidance on the different volumes of mannitol required (depending on concentration)
 
- When used pre-operatively, the dose should be administered 60 to 90 minutes before surgery to obtain the maximum effect
 
Use in patients with oliguria or renal impairment
- A test dose (to assess renal function) of about 0.2g per kg should be administered over three to five minutes - this should produce a diuresis of at least 30 to 50ml/hour during the next two to three hours
 
- A second test dose may be given if there is inadequate response to the first test dose
 
- See table above for guidance on the different volumes of mannitol required (depending on concentration)
 
- If the second test dose does not produce an adequate urine output, then need to reassess management
 
Acute renal failure
- The general dose range for adults is 50 to 200g mannitol in a 24 hour period, with a dosage limit of 50g mannitol on any one occasion
 
- In most instances, adequate response will be achieved at a dosage of 50 to 100g mannitol per day
 
- The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50mL/hour
 
- See table above for guidance on the different volumes of mannitol required (depending on concentration)
 
Promotion of elimination of renally excreted toxic substances in poisoning
- An initial loading dose of 25g may be given
 
- Adjust dose to maintain urinary output of at least 100ml/hour and positive fluid balance of 1 to 2 litres
 
- See table above for guidance on the different volumes of mannitol required (depending on concentration)
 
Renal impairment
- Use with caution in severe renal impairment
 
- If the second test dose does not produce adequate urine output, reassess options
 
      
  
        Monitoring
  
                  
- Renal function, fluid balance, serum electrolytes, serum and urine osmolality
 
- Monitor central venous pressure
 
- Assess cardiac function before and during treatment
 
      
  
        Storage
  
                  
- Store between 20 and 300C (ref 1)
 
- Do not refrigerate or freeze
 
- Solutions may crystallise, especially if stored at low temperatures
 
- The administration set should contain a 15 micron in-line filter  - see under method of administration above
 
Crystals may be redissolved by warming before use as follows:
- Re-dissolve any crystals by warming to 370C (Baxter products), or 600C (Fresenius Kabi products) (ref 1)
 
- Use of dry heat (eg warming cabinet) is recommended - solutions should not be heated in water due to risk of contamination
 
- Shake vigorously occasionally (ref 1)
 
- Microwave heating should not be used 
 
- The product should be allowed to cool to 370C before infusion
 
      
  
        References
  
                  SPC March 2019
1. Injectable medicines administration guide, Medusa Accessed online 7th July 2023
2. BNF- accessed online 7th July 2023
      
  
        Therapeutic classification
  
                  Osmotic diuretic